Cargando…

Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study

BACKGROUND: Fibroblast growth factor 23 (FGF23) is emerging as a novel biomarker of bone metabolism, chronic kidney disease, and cardiovascular disease (CVD). However, its clinical correlates and potential predictive role in a community‐based setting are incompletely understood. METHODS AND RESULTS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Haring, Robin, Enserro, Danielle, Xanthakis, Vanessa, Mitchell, Gary F., Benjamin, Emelia J., Hamburg, Naomi M., Sullivan, Lisa, Nauck, Matthias, Wallaschofski, Henri, Vasan, Ramachandran S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015386/
https://www.ncbi.nlm.nih.gov/pubmed/27385427
http://dx.doi.org/10.1161/JAHA.116.003486
_version_ 1782452431899066368
author Haring, Robin
Enserro, Danielle
Xanthakis, Vanessa
Mitchell, Gary F.
Benjamin, Emelia J.
Hamburg, Naomi M.
Sullivan, Lisa
Nauck, Matthias
Wallaschofski, Henri
Vasan, Ramachandran S.
author_facet Haring, Robin
Enserro, Danielle
Xanthakis, Vanessa
Mitchell, Gary F.
Benjamin, Emelia J.
Hamburg, Naomi M.
Sullivan, Lisa
Nauck, Matthias
Wallaschofski, Henri
Vasan, Ramachandran S.
author_sort Haring, Robin
collection PubMed
description BACKGROUND: Fibroblast growth factor 23 (FGF23) is emerging as a novel biomarker of bone metabolism, chronic kidney disease, and cardiovascular disease (CVD). However, its clinical correlates and potential predictive role in a community‐based setting are incompletely understood. METHODS AND RESULTS: We evaluated participants of the Framingham Heart Study (seventh examination cycle of the Offspring cohort plus second examination cycle of the multiethnic Omni cohort) to identify clinical correlates of plasma FGF23 (N=3236) and examine its cross‐sectional association with vascular function (N=2209), and longitudinal association with 10‐year incidence of CVD (N=2823), and all‐cause mortality (N=3223). Circulating FGF23 concentrations were positively related to African‐American and Asian ethnicity, waist circumference, current smoking, serum glucose, history of CVD, and antihypertensive medication use; and negatively related to male sex, hormone replacement therapy, and estimated glomerular filtration rate. Multivariable‐adjusted cross‐sectional analyses showed no consistent association of FGF23 with vascular function measures. During a median follow‐up time of 10.8 years, 347 incident CVD events and 412 deaths occurred. Multivariable‐adjusted Cox regression models revealed a positive association of FGF23 with all‐cause mortality (hazard ratio [HR] per SD increase, 1.31; 95% CI, 1.20–1.42), but not with incident CVD (HR per SD increase, 1.05; 95% CI, 0.94–1.17). CONCLUSIONS: In our large, community‐based sample, FGF23 was associated with mortality risk, but not with vascular function or incident CVD.
format Online
Article
Text
id pubmed-5015386
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-50153862016-09-19 Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study Haring, Robin Enserro, Danielle Xanthakis, Vanessa Mitchell, Gary F. Benjamin, Emelia J. Hamburg, Naomi M. Sullivan, Lisa Nauck, Matthias Wallaschofski, Henri Vasan, Ramachandran S. J Am Heart Assoc Original Research BACKGROUND: Fibroblast growth factor 23 (FGF23) is emerging as a novel biomarker of bone metabolism, chronic kidney disease, and cardiovascular disease (CVD). However, its clinical correlates and potential predictive role in a community‐based setting are incompletely understood. METHODS AND RESULTS: We evaluated participants of the Framingham Heart Study (seventh examination cycle of the Offspring cohort plus second examination cycle of the multiethnic Omni cohort) to identify clinical correlates of plasma FGF23 (N=3236) and examine its cross‐sectional association with vascular function (N=2209), and longitudinal association with 10‐year incidence of CVD (N=2823), and all‐cause mortality (N=3223). Circulating FGF23 concentrations were positively related to African‐American and Asian ethnicity, waist circumference, current smoking, serum glucose, history of CVD, and antihypertensive medication use; and negatively related to male sex, hormone replacement therapy, and estimated glomerular filtration rate. Multivariable‐adjusted cross‐sectional analyses showed no consistent association of FGF23 with vascular function measures. During a median follow‐up time of 10.8 years, 347 incident CVD events and 412 deaths occurred. Multivariable‐adjusted Cox regression models revealed a positive association of FGF23 with all‐cause mortality (hazard ratio [HR] per SD increase, 1.31; 95% CI, 1.20–1.42), but not with incident CVD (HR per SD increase, 1.05; 95% CI, 0.94–1.17). CONCLUSIONS: In our large, community‐based sample, FGF23 was associated with mortality risk, but not with vascular function or incident CVD. John Wiley and Sons Inc. 2016-07-06 /pmc/articles/PMC5015386/ /pubmed/27385427 http://dx.doi.org/10.1161/JAHA.116.003486 Text en © 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Haring, Robin
Enserro, Danielle
Xanthakis, Vanessa
Mitchell, Gary F.
Benjamin, Emelia J.
Hamburg, Naomi M.
Sullivan, Lisa
Nauck, Matthias
Wallaschofski, Henri
Vasan, Ramachandran S.
Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study
title Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study
title_full Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study
title_fullStr Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study
title_full_unstemmed Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study
title_short Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study
title_sort plasma fibroblast growth factor 23: clinical correlates and association with cardiovascular disease and mortality in the framingham heart study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015386/
https://www.ncbi.nlm.nih.gov/pubmed/27385427
http://dx.doi.org/10.1161/JAHA.116.003486
work_keys_str_mv AT haringrobin plasmafibroblastgrowthfactor23clinicalcorrelatesandassociationwithcardiovasculardiseaseandmortalityintheframinghamheartstudy
AT enserrodanielle plasmafibroblastgrowthfactor23clinicalcorrelatesandassociationwithcardiovasculardiseaseandmortalityintheframinghamheartstudy
AT xanthakisvanessa plasmafibroblastgrowthfactor23clinicalcorrelatesandassociationwithcardiovasculardiseaseandmortalityintheframinghamheartstudy
AT mitchellgaryf plasmafibroblastgrowthfactor23clinicalcorrelatesandassociationwithcardiovasculardiseaseandmortalityintheframinghamheartstudy
AT benjaminemeliaj plasmafibroblastgrowthfactor23clinicalcorrelatesandassociationwithcardiovasculardiseaseandmortalityintheframinghamheartstudy
AT hamburgnaomim plasmafibroblastgrowthfactor23clinicalcorrelatesandassociationwithcardiovasculardiseaseandmortalityintheframinghamheartstudy
AT sullivanlisa plasmafibroblastgrowthfactor23clinicalcorrelatesandassociationwithcardiovasculardiseaseandmortalityintheframinghamheartstudy
AT nauckmatthias plasmafibroblastgrowthfactor23clinicalcorrelatesandassociationwithcardiovasculardiseaseandmortalityintheframinghamheartstudy
AT wallaschofskihenri plasmafibroblastgrowthfactor23clinicalcorrelatesandassociationwithcardiovasculardiseaseandmortalityintheframinghamheartstudy
AT vasanramachandrans plasmafibroblastgrowthfactor23clinicalcorrelatesandassociationwithcardiovasculardiseaseandmortalityintheframinghamheartstudy